Processa Pharmaceuticals Inc PCSA

Healthcare

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).

NDAQ:PCSA - Post by User

Processa Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Apr 25, 2024 10:15am

24 Views

Post# 36006997

US Companies Moving the Markets, Morning edition <br>Thu, Ap

BREAKING NEWS: $PCSA US Companies Moving the Markets, Morning edition <br>Thu, Apr 25, 2024 as of 10.00 am ETA look at the top 10 most actives in the United States Safe & Green Holdings Corp. (SGBX) rose 52.1% to $0.2192 on volume of 34,842,044 shares Processa Pharmaceuticals Inc. (PCSA) rose 46.9% to $2.38 on volume of 31,858,013 shares PROSHARES TRUST (SQQQ) rose 5.0% to $12.4002 on volume...PCSA - US Companies Moving the Markets, Morning edition <br>Thu, Apr 25, 2024 as of 10.00 am ET

<< Previous

Bullboard Posts

Next >>

Silvercorp to expand into Ecuador with C$200M Adventus acquisition